{"id":57016,"date":"2026-02-12T22:37:20","date_gmt":"2026-02-12T14:37:20","guid":{"rendered":"https:\/\/flcube.com\/?p=57016"},"modified":"2026-02-12T22:37:23","modified_gmt":"2026-02-12T14:37:23","slug":"ribo-life-science-licenses-4-4-billion-mash-sirna-portfolio-to-madrigal-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57016","title":{"rendered":"Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals"},"content":{"rendered":"\n

Suzhou Ribo Life Science Co., Ltd.<\/strong> (HKG:\u202f6938<\/a><\/strong>) has entered a landmark licensing agreement<\/strong> with Madrigal Pharmaceuticals, Inc.<\/strong> (NASDAQ:\u202fMDGL<\/a><\/strong>), the global leader in metabolic dysfunction-associated steatohepatitis (MASH) therapeutics<\/strong>, to jointly develop six innovative siRNA therapies<\/strong> leveraging Ribo’s proprietary liver-targeting RiboGalSTAR platform<\/strong>. The deal, valued at up to USD\u202f4.4 billion<\/strong>, represents one of the largest RNA therapeutic partnerships<\/strong> in the rapidly expanding MASH market<\/strong>.<\/p>\n\n\n\n

Transaction Structure<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938)<\/td><\/tr>
Licensee<\/strong><\/td>Madrigal Pharmaceuticals, Inc. (NASDAQ:\u202fMDGL)<\/td><\/tr>
Technology Platform<\/strong><\/td>RiboGalSTAR<\/strong> \u2013 Liver-targeting siRNA delivery system<\/td><\/tr>
Assets<\/strong><\/td>Six preclinical siRNA therapies<\/strong> (single-target and dual-target)<\/td><\/tr>
Rights Granted<\/strong><\/td>Global exclusive<\/strong> R&D and commercialization rights<\/td><\/tr>
Upfront Payment<\/strong><\/td>USD\u202f60 million<\/strong><\/td><\/tr>
Total Deal Value<\/strong><\/td>Up to USD\u202f4.4 billion<\/strong> (upfront + milestones)<\/td><\/tr>
Milestones<\/strong><\/td>Clinical development, regulatory approvals, commercial sales<\/td><\/tr>
Royalties<\/strong><\/td>Tiered royalties on global net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Platform: RiboGalSTAR<\/h2>\n\n\n\n
Feature<\/th>RiboGalSTAR Specification<\/th>Strategic Advantage<\/th><\/tr><\/thead>
Target Organ<\/strong><\/td>Liver-specific delivery<\/strong><\/td>Addresses MASH pathophysiology<\/strong> at disease site<\/td><\/tr>
Mechanism<\/strong><\/td>siRNA (small interfering RNA)<\/strong> \u2013 gene silencing<\/td>Durable, reversible<\/strong> knockdown of disease-driving genes<\/td><\/tr>
Galactose Targeting<\/strong><\/td>ASGPR (asialoglycoprotein receptor) mediated uptake<\/strong><\/td>High hepatocyte specificity<\/strong>; reduced off-target effects<\/td><\/tr>
Single\/Dual Target<\/strong><\/td>Multi-gene silencing capability<\/strong><\/td>Synergistic efficacy<\/strong>; resistance prevention<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Market Context<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
MASH Market Scale<\/strong><\/td>>$20 billion by 2030<\/strong>; resmetirom (Rezdiffra)<\/strong> first approved 2024; massive unmet need<\/strong> for combination and next-generation therapies<\/strong><\/td><\/tr>
Madrigal Leadership<\/strong><\/td>Resmetirom FDA approval<\/strong> establishes MASH commercial infrastructure<\/strong>; siRNA pipeline<\/strong> complements small molecule franchise<\/strong> for combination strategies<\/strong><\/td><\/tr>
Ribo Platform Validation<\/strong><\/td>$4.4 billion deal<\/strong> validates RiboGalSTAR<\/strong> as best-in-class liver-targeting siRNA technology<\/strong>; China-to-global biotech success story<\/strong><\/td><\/tr>
siRNA MASH Differentiation<\/strong><\/td>Gene silencing<\/strong> offers disease-modifying potential<\/strong> vs. symptomatic management<\/strong>; quarterly dosing<\/strong> possible vs. daily oral resmetirom<\/strong><\/td><\/tr>
Competitive Landscape<\/strong><\/td>Arrowhead, Alnylam, Ionis<\/strong> pursuing MASH siRNA; Ribo-Madrigal partnership<\/strong> creates formidable challenger<\/strong> with combined expertise<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercial Outlook<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>Technology transfer; lead candidate selection from 6-asset portfolio<\/td>2026<\/td><\/tr>
Preclinical<\/strong><\/td>IND-enabling studies; GLP toxicology<\/td>2026-2027<\/td><\/tr>
Clinical<\/strong><\/td>Phase I\/II MASH trials (combination with resmetirom potential)<\/td>2027-2028<\/td><\/tr>
Regulatory<\/strong><\/td>NDA submissions; global commercialization<\/td>2029+<\/td><\/tr>
Royalties<\/strong><\/td>Revenue participation based on Madrigal global sales<\/td>Commercial launch<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Ribo Life Science siRNA clinical development, Madrigal Pharmaceuticals’ MASH market expansion, and RiboGalSTAR platform validation in liver diseases. Actual results may differ due to siRNA delivery efficiency challenges, combination therapy safety profiles, and competitive dynamics with Arrowhead and Alnylam in MASH.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) has entered a landmark licensing agreement with Madrigal…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4524,1395,1396,76,1725,64],"class_list":["post-57016","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-6938","tag-madrigal-pharmaceuticals","tag-nasdaq-mdgl","tag-nash","tag-ribo-life-science","tag-rnai-aso"],"yoast_head":"\nRibo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) has entered a landmark licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:\u202fMDGL), the global leader in metabolic dysfunction-associated steatohepatitis (MASH) therapeutics, to jointly develop six innovative siRNA therapies leveraging Ribo's proprietary liver-targeting RiboGalSTAR platform. The deal, valued at up to USD\u202f4.4 billion, represents one of the largest RNA therapeutic partnerships in the rapidly expanding MASH market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57016\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) has entered a landmark licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:\u202fMDGL), the global leader in metabolic dysfunction-associated steatohepatitis (MASH) therapeutics, to jointly develop six innovative siRNA therapies leveraging Ribo's proprietary liver-targeting RiboGalSTAR platform. The deal, valued at up to USD\u202f4.4 billion, represents one of the largest RNA therapeutic partnerships in the rapidly expanding MASH market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57016\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-12T14:37:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-12T14:37:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57016#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57016\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals\",\"datePublished\":\"2026-02-12T14:37:20+00:00\",\"dateModified\":\"2026-02-12T14:37:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57016\"},\"wordCount\":396,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 6938\",\"Madrigal Pharmaceuticals\",\"NASDAQ: MDGL\",\"NASH\",\"Ribo Life Science\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57016#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57016\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57016\",\"name\":\"Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-12T14:37:20+00:00\",\"dateModified\":\"2026-02-12T14:37:23+00:00\",\"description\":\"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) has entered a landmark licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:\u202fMDGL), the global leader in metabolic dysfunction-associated steatohepatitis (MASH) therapeutics, to jointly develop six innovative siRNA therapies leveraging Ribo's proprietary liver-targeting RiboGalSTAR platform. The deal, valued at up to USD\u202f4.4 billion, represents one of the largest RNA therapeutic partnerships in the rapidly expanding MASH market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57016#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57016\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57016#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals - Insight, China's Pharmaceutical Industry","description":"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) has entered a landmark licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:\u202fMDGL), the global leader in metabolic dysfunction-associated steatohepatitis (MASH) therapeutics, to jointly develop six innovative siRNA therapies leveraging Ribo's proprietary liver-targeting RiboGalSTAR platform. The deal, valued at up to USD\u202f4.4 billion, represents one of the largest RNA therapeutic partnerships in the rapidly expanding MASH market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57016","og_locale":"en_US","og_type":"article","og_title":"Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals","og_description":"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) has entered a landmark licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:\u202fMDGL), the global leader in metabolic dysfunction-associated steatohepatitis (MASH) therapeutics, to jointly develop six innovative siRNA therapies leveraging Ribo's proprietary liver-targeting RiboGalSTAR platform. The deal, valued at up to USD\u202f4.4 billion, represents one of the largest RNA therapeutic partnerships in the rapidly expanding MASH market.","og_url":"https:\/\/flcube.com\/?p=57016","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-12T14:37:20+00:00","article_modified_time":"2026-02-12T14:37:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57016#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57016"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals","datePublished":"2026-02-12T14:37:20+00:00","dateModified":"2026-02-12T14:37:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57016"},"wordCount":396,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 6938","Madrigal Pharmaceuticals","NASDAQ: MDGL","NASH","Ribo Life Science","RNAi \/ ASO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57016#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57016","url":"https:\/\/flcube.com\/?p=57016","name":"Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-12T14:37:20+00:00","dateModified":"2026-02-12T14:37:23+00:00","description":"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) has entered a landmark licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:\u202fMDGL), the global leader in metabolic dysfunction-associated steatohepatitis (MASH) therapeutics, to jointly develop six innovative siRNA therapies leveraging Ribo's proprietary liver-targeting RiboGalSTAR platform. The deal, valued at up to USD\u202f4.4 billion, represents one of the largest RNA therapeutic partnerships in the rapidly expanding MASH market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57016#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57016"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57016#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57016"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57016\/revisions"}],"predecessor-version":[{"id":57018,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57016\/revisions\/57018"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}